|Bid||5.95 x 800|
|Ask||6.40 x 800|
|Day's Range||5.94 - 6.23|
|52 Week Range||5.94 - 19.35|
|Beta (3Y Monthly)||1.27|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 2, 2018 - May 7, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||26.50|
Out of thousands of stocks that are currently traded on the market, it is difficult to determine those that can really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]
NEW YORK, Dec. 06, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
BOSTON, Dec. 03, 2018 -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of.
Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced dosing of the first patient in a Phase 2 study evaluating the potential efficacy and safety of oral and intravenous (IV) omadacycline for the treatment of acute pyelonephritis, a common subset of complicated urinary tract infections (cUTI). “Urinary tract infection is one of the most commonly diagnosed bacterial infections and treating clinicians are limited by a lack of broad-spectrum, well-tolerated, once-daily oral antibiotics,” said Evan Loh, M.D., President, Chief Operating Officer and Chief Medical Officer of Paratek. “This important milestone signifies continued progress in the evaluation of the efficacy and safety of omadacycline, which has the potential to address this significant unmet need in this serious community-acquired infection.
Every investor in Paratek Pharmaceuticals Inc (NASDAQ:PRTK) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it’s not unusual to see Read More...
Paratek (PRTK) delivered earnings and revenue surprises of -18.82% and -99.15%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Boston-based company said it had a loss of $1.01 per share. The results missed Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of ...
--NUZYRA™ (omadacycline) approved by FDA for the treatment of CABP and ABSSSI -- -- SEYSARA™ (sarecycline) approved by FDA for the treatment of moderate to severe acne vulgaris.
Paratek Pharmaceuticals, Inc. (PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, announced today that on October 31, 2018, the Company granted stock options and restricted stock units to two new employees of the Company. The stock options are to acquire, in the aggregate, 7,100 shares of the Company’s common stock at a per share exercise price of $7.45, the closing sales price on October 31, 2018, and shall vest over a four-year vesting period, under which 25% of the shares will vest after 12 months of employment, with the remaining shares vesting monthly thereafter over the remaining 36-month period, subject to the employee’s continuous service.
Paratek Pharmaceuticals, Inc. (PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, announced today that it will host a conference call and live audio webcast on Tuesday, November 6, 2018 at 4:30 p.m. EDT to report third quarter 2018 financial results and provide a corporate update. Domestic investors wishing to participate in the call should dial: 877-407-0792 and international investors should dial: 201-689-8263. Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry.
NEW YORK, Oct. 26, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
In a world where superbugs are overpowering various antibiotic drugs, threatening millions of lives, Massachusetts biotechs are fighting hard to ensure the bugs don't become the industry's kryptonite.
As we recently mentioned, biotech stocks have been particularly hammered over the last few weeks. Unfortunately, that’s meant that many biotech stocks have been hit hard. The market rout has caused many biotech stocks to drop to single or low double-digit prices.
HENDERSON, NV / ACCESSWIRE / October 5, 2018 / The NASDAQ Biotech Index is up 13% over the past six months. With several large announcements seemingly on the horizon this trend should continue into the ...
Paratek Pharmaceuticals (PRTK) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
The company announced FDA approval of Nuzyra, for the treatment of community-acquired bacterial pneumonia (CABP), as well as acute skin infections. Paratek has developed plans to conduct marketing studies in pediatrics and other areas.
The latest FDA approval secured by Paratek is for an antibiotic developed to treat community-acquired bacterial pneumonia and acute skin and skin structure infections.
Paratek (PRTK) gets FDA approval for Nuzyra for the treatment of serious community-acquired bacterial infections and Seysara for the treatment of acne.
Investors need to pay close attention to Paratek Pharmaceuticals (PRTK) stock based on the movements in the options market lately.
NEW YORK, NY / ACCESSWIRE / October 3, 2018 / Wall Street closed mostly lower on Tuesday with the Dow Jones posting its fourth consecutive daily gain, however broader market dropped over trade related ...
TRENTON, N.J. (AP) — U.S. regulators on Tuesday approved a modernized version of a decades-old antibiotic used to treat a number of infections.